The synergistic effects of the combination therapy involving avapritinib and lenvatinib were evaluated in both PDGFRA-high and PDGFRA-low HCC cell lines, including those exhibiting LR. This evidence concerns the gene PDGFRA and hepatocellular carcinoma.